Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The First Affiliated Hospital of Soochow University | OTHER |
| The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China | OTHER |
| Jiangsu Cancer Institute & Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Is elective nodal irradiation (ENI) necessary for patients with thoracic esophageal cancer after esophagectomy and with pathological stage of T1-2,N+,M0?
Patient Population:
Thoracic esophageal squamous cell carcinoma after esophagectomy with at least 15 lymph nodes removed for adequate nodal staging.
R0 resection; T1-2, N+, M0.
Scheme:
After esophagectomy, patients are firstly stratified by numbers of lymph node metastasis (<3 or >=3). Then patients are randomized to 2 arms:
Arm A:
Adjuvant chemotherapy (4 cycles).
Arm B:
Adjuvant chemotherapy (4 cycles) + Elective Nodal Irradiation (bilateral supraclavicular fossa and mediastinum).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| B | Experimental | After esophagectomy, patients in Arm B will receive adjuvant chemotherapy, followed by elective nodal irradiation (ENI) |
|
| A | Active Comparator | After esophagectomy, patients in Arm A will receive adjuvant chemotherapy only |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Elective nodal irradiation (ENI) | Radiation |
| ||
| Adjuvant chemotherapy only |
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | To evaluate elective nodal irradiation (ENI) is better for the overall survival of patients with thoracic esophageal cancer after esophagectomy who with pathological stage of T1-2, N positive, M0 |
| Measure | Description | Time Frame |
|---|---|---|
| Locoregional control rate | ||
| Safety and Tolerability (incidence rate of adverse events) | the incidence rate of adverse events, especially radiation-induced lung toxicity |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Multiple primary esophageal tumors
Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years (For example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible).
Severe, active comorbidity, defined as follows:
3.1 Unstable angina and/or congestive heart failure requiring hospitalization within the last 3 months 3.2 Transmural myocardial infarction within the last 6 months 3.3 Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration 3.4 Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration 3.5 Acquired immune deficiency syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol. The need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.
Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception.
Prior systemic chemotherapy, prior radiation therapy or prior target drug therapy
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Xu-Wei Cai, M.D., Ph.D. | Contact | 8621-64175590 | 1504 | birdhome2000@hotmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fudan University Cancer Center | Recruiting | Shanghai | Shanghai Municipality | 200032 | China |
Not provided
| Affiliated Hospital of Jiangsu University | OTHER |
| Zhejiang Cancer Hospital | OTHER |
| First Affiliated Hospital of Wenzhou Medical University | OTHER |
| Zhejiang University | OTHER |
| The First Affiliated Hospital of Anhui Medical University | OTHER |
| Anhui Provincial Hospital | OTHER_GOV |
| Fujian Cancer Hospital | OTHER_GOV |
| Shanghai Chest Hospital | OTHER |
| Shanghai Pulmonary Hospital, Shanghai, China | OTHER |
| RenJi Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Failure pattern | To evaluate the rationality of ENI after esophagectomy by analyzing the therapeutic failure patterns especially by comparing the in-field and out-of-field recurrences |
| ID | Term |
|---|---|
| D000077277 | Esophageal Squamous Cell Carcinoma |
| ID | Term |
|---|---|
| D002294 | Carcinoma, Squamous Cell |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D018307 | Neoplasms, Squamous Cell |
| D004938 | Esophageal Neoplasms |
| D005770 | Gastrointestinal Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D006258 | Head and Neck Neoplasms |
| D004066 | Digestive System Diseases |
| D004935 | Esophageal Diseases |
| D005767 | Gastrointestinal Diseases |
Not provided
Not provided